Christopher Peetz
Founder presso MIRUM PHARMACEUTICALS, INC.
Patrimonio netto: 8 M $ in data 31/03/2024
Profilo
Mr. Christopher Peetz is a Chief Executive Officer & Director at Mirum Pharmaceuticals, Inc., an Independent Director at Alpine Immune Sciences, Inc. and a Chief Executive Officer at Satiogen Pharmaceuticals, Inc. He is on the Board of Directors at Mirum Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc. Mr. Peetz was previously employed as a Chief Executive Officer by Flashlight Therapeutics, Inc., a Chief Financial Officer & Head-Development by Tobira Therapeutics, Inc., a Chief Financial Officer & Head-Development by Tobira Therapeutics, Inc. /Old/, a Vice President-Finance & Development by Jennerex Biotherapeutics, Inc., a Senior Director-Corporate Development & Strategy by Onyx Pharmaceuticals, Inc., and a Principal by TerraVia Holdings, Inc. He received his undergraduate degree from Washington University in St. Louis and an MBA from Stanford Graduate School of Business.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
02/02/2024 | 305 682 ( 0.66% ) | 8 M $ | 31/03/2024 | |
02/01/2024 | 1 900 ( 0.00% ) | 75 316 $ | 31/03/2024 |
Posizioni attive di Christopher Peetz
Società | Posizione | Inizio |
---|---|---|
ALPINE IMMUNE SCIENCES, INC. | Director/Board Member | 24/04/2018 |
MIRUM PHARMACEUTICALS, INC. | Founder | 07/05/2018 |
Satiogen Pharmaceuticals, Inc.
Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Chief Executive Officer | - |
Precedenti posizioni note di Christopher Peetz
Società | Posizione | Fine |
---|---|---|
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | 01/12/2016 |
TOBIRA THERAPEUTICS INC | Director of Finance/CFO | 01/12/2016 |
Flashlight Therapeutics, Inc.
Flashlight Therapeutics, Inc. BiotechnologyHealth Technology Flashlight Therapeutics, Inc. develops therapeutics for unmet medical needs. | Chief Executive Officer | 01/12/2019 |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/03/2014 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01/01/2012 |
Formazione di Christopher Peetz
Washington University in St. Louis | Undergraduate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
MIRUM PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 7 |
---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
TerraVia Holdings, Inc.
TerraVia Holdings, Inc. Household/Personal CareConsumer Non-Durables TerraVia Holdings, Inc. engaged in the production of food, nutrition, and specialty ingredients from algae. It produced oils, specialty fats, and powdered ingredients using its microalgae-based technology platform. The company was founded by Jonathan S. Wolfson and Harrison F. Dillon on March 31, 2003 and was headquartered in San Francisco, CA. | Consumer Non-Durables |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Satiogen Pharmaceuticals, Inc.
Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Commercial Services |
Tobira Therapeutics, Inc.
Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ. | Health Technology |
Flashlight Therapeutics, Inc.
Flashlight Therapeutics, Inc. BiotechnologyHealth Technology Flashlight Therapeutics, Inc. develops therapeutics for unmet medical needs. | Health Technology |
- Borsa valori
- Insiders
- Christopher Peetz